GSK new ICS/LABA drug Wanruishu ® officially enter the Chinese market
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, GSK China announced that its new ICS/LABADrug(http://Wanruishu ® (generic name: fluoroteason/Verantro, FF/VI) has officially entered the Chinese marketas the only once-a-day ICS/LABA drug on the market, Wanruishu ® help improve the management of respiratory slow diseaseThe new ICS/LABA VanReisu ® contains two drug ingredients, fluorobutiasone rhododendasone is more anti-inflammatory, while Verantro can provide a 24-hour long-acting bronchosacho diastolic effect, two drug interactions to help more asthma patients improve asthma control, reduce acute exacerbation in patients with moderate to severe slow-resisting lung
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
